Roche lung cancer drug Alecensa slashes brain risk in tests
(Reuters) - Patients taking Roche's targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer's Xalkori, new clinical trial data show.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Health | Lung Cancer | Neurology | Pfizer